Synthesis and anti-tumor activity of a fluorinated analog of medroxyprogesterone acetate (MPA), 9α-fluoromedroxyprogesterone acetate (FMPA)

3Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

We synthesized 9α-fluoromedroxyprogesterone acetate (FMPA) in order to test whether it is a more potent anti-angiogenic agent than medroxyprogesterone acetate (MPA), which has been widely used as a therapeutic agent for breast and endometrium cancers. FMPA was previously synthesized in 10 steps (total yield: 1%). An efficient synthesis of FMPA has been achieved in 6 steps (total yield: 12%). We examined the anti-tumor effect of FMPA, complexed with dimethyl-β-cyclodextrin (DM-β-CyD), on rat mammary carcinomas induced by 7,12-dimethylbenz[a]anthracene (DMBA). FMPA showed great anti-tumor effect on DMBA-induced rat mammary carcinomas. © 2006 Pharmaceutical Society of Japan.

Cite

CITATION STYLE

APA

Murata, N., Fujimori, S., Ichihara, Y., Sato, Y., Yamaji, T., Tsuboi, H., … Hibino, S. (2006). Synthesis and anti-tumor activity of a fluorinated analog of medroxyprogesterone acetate (MPA), 9α-fluoromedroxyprogesterone acetate (FMPA). Chemical and Pharmaceutical Bulletin, 54(11), 1567–1570. https://doi.org/10.1248/cpb.54.1567

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free